Fanhua Holdings (FANH.US) announced on Friday that its health platform, Fanlan Cross Health, has signed a strategic cooperation agreement with Shanghai Baoteng Biotechnology.

According to the agreement, the two parties will cooperate in the fields of medical testing, health management, and modern high-end medical treatment and health management services such as cell therapy.

As of the time of writing, Fanhua Holdings' stock has risen 0.79% before the market opens.